The Claim
In adults with preexisting cardiovascular disease and obesity but without diabetes, treatment with once-weekly subcutaneous semaglutide at a dose of 2.4 mg results in a 16.6% rate of permanent treatment discontinuation due to adverse events, compared to an 8.2% rate with placebo, indicating more than a twofold higher risk of discontinuation because of side effects with semaglutide.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults with heart disease and obesity who don’t have diabetes, taking a weekly semaglutide shot (2.4 mg) leads to more than twice as many people stopping treatment because of side effects compared to those taking a dummy shot.
See the scientific wording
In adults with preexisting cardiovascular disease and obesity without diabetes, treatment with once-weekly subcutaneous semaglutide at 2.4 mg leads to permanent discontinuation in 16.6% of patients due to adverse events, compared to 8.2% with placebo, indicating a more than twofold higher risk of stopping treatment because of side effects.
What the research says
1 studyStudy: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The study looked at the exact same medicine and patients as the claim, and it found the same numbers: about 16.6% stopped semaglutide due to side effects, compared to 8.2% on placebo.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.